Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CStone Approved to Start China Bridging Trial of GIST Candidate

publication date: Apr 15, 2019

Suzhou's CStone Pharma (HK: 2616) was approved to start a bridging Phase I/II clinical trial in China of avapritinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). In June 2018, CStone acquired China rights to avapritinib and two other oral genomic-based potential cancer agents from Blueprint Medicine of the US in a deal worth up to $386 million. The goal of the Phase I/II bridging study is to allow CStone to participate in the global Phase III trial of the candidate. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China